Literature DB >> 8197562

Repeat hepatectomy for recurrent hepatocellular carcinoma.

M Shimada1, T Matsumata, A Taketomi, K Yamamoto, H Itasaka, K Sugimachi.   

Abstract

BACKGROUND: The significance of repeat hepatectomy for recurrent hepatocellular carcinoma remains controversial. Therefore the aim of this study was to reevaluate both the survival and the surgical risks of repeat hepatectomy.
METHODS: The significance of repeat hepatectomy including the survival and the surgical risks for recurrent hepatocellular carcinoma were investigated with 21 patients who underwent a curative repeat hepatectomy during the period between May 1975 and July 1993. For a comparison of survival, 253 patients who underwent a curative primary hepatectomy during the period between April 1985 and July 1993 were used. Moreover, the preoperative liver function tests were also compared between the first and second hepatectomies.
RESULTS: Regarding the preoperative liver function tests, the indocyanine green dye excretion rate at 15 minutes in the second hepatectomy (18.7% +/- 8.7%) was significantly higher than that in the first hepatectomy (14.7% +/- 5.9%). With regard to the surgical risks, there was no difference in the clinical parameters for blood loss, operation time, and the incidence of postoperative complications between the first and second hepatectomies. The postoperative hospital stay for the second hepatectomies was relatively shorter than that for the first hepatectomies. In addition, the patient's survival and disease-free survival after a curative repeat hepatectomy were almost identical to that after a curative primary hepatectomy.
CONCLUSIONS: A curative repeat hepatectomy is thus considered to be the most effective therapeutic modality for recurrent hepatocellular carcinoma.

Entities:  

Mesh:

Year:  1994        PMID: 8197562

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  8 in total

1.  Factors associated with disease survival after surgical resection in Chinese patients with hepatocellular carcinoma.

Authors:  Li Qiang; Li Huikai; Kelly Butt; P Peter Wang; Xishan Hao
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

Review 2.  Effect of liver regeneration on malignant hepatic tumors.

Authors:  Ji-Hua Shi; Pål-Dag Line
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

3.  Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma.

Authors:  M Shimada; K Takenaka; K Taguchi; Y Fujiwara; T Gion; K Kajiyama; T Maeda; K Shirabe; K Yanaga; K Sugimachi
Journal:  Ann Surg       Date:  1998-01       Impact factor: 12.969

Review 4.  Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma.

Authors:  R Tung-Ping Poon; S T Fan; J Wong
Journal:  Ann Surg       Date:  2000-07       Impact factor: 12.969

5.  Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors.

Authors:  R T Poon; S T Fan; C M Lo; C L Liu; J Wong
Journal:  Ann Surg       Date:  1999-02       Impact factor: 12.969

6.  Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation.

Authors:  Charles H Cha; Leyo Ruo; Yuman Fong; William R Jarnagin; Jinru Shia; Leslie H Blumgart; Ronald P DeMatteo
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

7.  Long-term outcomes following aggressive management of recurrent hepatocellular carcinoma after upfront liver resection.

Authors:  Hadrien Tranchart; Mircea Chirica; Ailton Sepulveda; Pierre-Philippe Massault; Filomena Conti; Olivier Scatton; Olivier Soubrane
Journal:  World J Surg       Date:  2012-11       Impact factor: 3.352

8.  Efficacy of re-resection versus radiofrequency ablation for recurrent Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma (HCC) after resection for primary HCC.

Authors:  Xieling Yin; Tianqi Hua; Chi Liang; Zhong Chen
Journal:  Transl Cancer Res       Date:  2019-08       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.